Jeremy Coplan
Psychosomatic Medicine · Manhasset, NYNPI 1346468600
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,619 of the $298,435 with a category attached, or 76.9%. It is spread thinly across 13 manufacturers, the largest accounting for just 19.4%. 2025 is the largest year on record at $67,636, 2.2 times the $30,402 reported in 2019. Among psychosomatic medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $601.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$58K
- AbbVie$53K
- Otsuka America Pharmaceutical, Inc.$43K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$43K
- Teva Pharmaceuticals USA, Inc.$41K
- Axsome Therapeutics, Inc.$21K
- plus $40K from 7 others
What the payments were for
- Consulting fees$43,12114%
- Speaking & faculty fees$229,61977%
- Travel & lodging$10,4193%
- Food & beverage$14,8365%
- Education$4400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 47 | $57,901 |
| AbbVie(2 entities) | 139 | $52,568 |
| Otsuka America Pharmaceutical, Inc. | 86 | $43,377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $43,149 |
| Teva Pharmaceuticals USA, Inc. | 38 | $40,951 |
| Axsome Therapeutics, Inc. | 21 | $20,867 |
| E.r. Squibb & Sons, L.L.C. | 39 | $16,927 |
| Sunovion Pharmaceuticals Inc. | 41 | $13,090 |
| Johnson & Johnson | 8 | $9,151 |
| Corium, LLC | 9 | $212 |
| Neurocrine Biosciences, Inc. | 3 | $181 |
| Shire North American Group Inc | 2 | $33 |
| Lundbeck LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$298,435 in reported general payments places this provider in the 95th percentile of 30 psychosomatic medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $162,103 |
| VraylarCariprazine Hcl | 92 | $125,731 |
| AuvelityDextromethorphan Hbr/Bupropion | 47 | $54,271 |
| RexultiBrexpiprazole | 29 | $52,638 |
| CaplytaLumateperone Tosylate | 26 | $45,661 |
| VyvanseLisdexamfetamine Dimesylate | 105 | $44,776 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $36,661 |
| ZoloftSertraline Hcl | 30 | $28,223 |
| Lurasidone Hcl | 124 | $22,850 |
| Aripiprazole | 152 | $17,528 |
| Modafinil | 15 | $15,851 |
| KlonopinClonazepam | 22 | $10,834 |
| Lamotrigine | 598 | $7,806 |
| Lisdexamfetamine Dimesylate | 24 | $7,549 |
| CymbaltaDuloxetine Hcl | 13 | $6,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $40,951 | $162,10318 claims |
| AbbVieVraylar | $52,568 | $125,73192 claims |
| Axsome Therapeutics, Inc.Auvelity | $20,867 | $54,27147 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $43,377 | $52,63829 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $43,149 | $45,66126 claims |
| Alkermes, Inc.Lybalvi | $57,901 | $36,66122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 psychosomatic medicine providers in New York.
Other psychosomatic medicine in Manhasset
- Claudia SickingerWhite Plains$3K
- Sasidhar GunturuBronx$3K
- Glen RamsayYonkers$1K
- Matthew RomanelliBriarcliff Manor$827
- Zorica Filipovic-JewellNew York$653
- David KrakowNew York$644
- Diana PunkoNew York$572
- Arkady BarenboimBrooklyn$561
- Guitelle St VictorEast Meadow$517
- Jena AndreuNew York$320
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.